[{"address1": "Ugland House", "address2": "PO Box 309", "city": "Grand Cayman", "zip": "KY1-1104", "country": "Cayman Islands", "phone": "848 230 7430", "website": "https://www.adlainortye.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of \u00df-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.", "fullTimeEmployees": 127, "companyOfficers": [{"maxAge": 1, "name": "Mr. Yang  Lu", "age": 43, "title": "CEO & Chairman", "yearBorn": 1980, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kaiyang  Tang", "age": 58, "title": "President", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Wei  Zhang", "age": 32, "title": "Chief Financial Officer", "yearBorn": 1991, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Victoria Elizabeth Demby Ph.D.", "age": 52, "title": "Senior VP & Global Head of Regulatory Affairs", "yearBorn": 1971, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ngai Chiu  Tse M.D., Ph.D.", "age": 55, "title": "Head of Research & Development", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 3.27, "open": 3.31, "dayLow": 3.12, "dayHigh": 3.3843, "regularMarketPreviousClose": 3.27, "regularMarketOpen": 3.31, "regularMarketDayLow": 3.12, "regularMarketDayHigh": 3.3843, "forwardPE": -4.216216, "volume": 31934, "regularMarketVolume": 31934, "averageVolume": 16067, "averageVolume10days": 38460, "averageDailyVolume10Day": 38460, "marketCap": 115128928, "fiftyTwoWeekLow": 1.85, "fiftyTwoWeekHigh": 17.48, "priceToSalesTrailing12Months": 23.025785, "fiftyDayAverage": 2.1948, "twoHundredDayAverage": 5.90398, "currency": "USD", "enterpriseValue": 286927520, "floatShares": 52398012, "sharesOutstanding": 31236900, "sharesShort": 3058, "sharesShortPriorMonth": 9329, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0001, "heldPercentInsiders": 0.06957, "heldPercentInstitutions": 0.00204, "shortRatio": 0.26, "shortPercentOfFloat": 0.0001, "impliedSharesOutstanding": 36900300, "bookValue": 1.446, "priceToBook": 2.1576762, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -54065000, "trailingEps": -6.18, "forwardEps": -1.62, "enterpriseToRevenue": 57.386, "enterpriseToEbitda": -4.514, "52WeekChange": -0.6826043, "SandP52WeekChange": 0.29098952, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ANL", "underlyingSymbol": "ANL", "shortName": "Adlai Nortye Ltd.", "longName": "Adlai Nortye Ltd.", "firstTradeDateEpochUtc": 1695994200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "291e650f-3a34-3dde-b7b9-4183619f74d0", "messageBoardId": "finmb_1830112145", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.12, "targetHighPrice": 9.0, "targetLowPrice": 9.0, "targetMeanPrice": 9.0, "targetMedianPrice": 9.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 1, "totalCash": 97987000, "totalCashPerShare": 0.885, "ebitda": -63570000, "totalDebt": 39528000, "quickRatio": 1.804, "currentRatio": 1.846, "totalRevenue": 5000000, "debtToEquity": 74.064, "revenuePerShare": 0.215, "returnOnAssets": -0.4641, "freeCashflow": -48734876, "operatingCashflow": -66700000, "grossMargins": 1.0, "operatingMargins": -12.9338, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-16"}]